Interleukins-6 −174G/C (rs1800795) and −572C/G (rs1800796) polymorphisms and prostate cancer risk

Autor: Iqbal, Muhammad Sarfaraz, Peng, Kaoqing, Sardar, Nimra, Iqbal, Muhammad Hasnain, Ghani, Muhammad Usman, Tanvir, Fouzia, Gu, Di, Guohua, Zeng, Duan, Xiaolu

Publikováno v: In Molecular Immunology December 2023 164:88-97

Association between CYP1A2 gene variants −163 C/A (rs762551) and −3860 G/A (rs2069514) and bladder cancer susceptibility.

Autor: Iqbal, Muhammad Sarfaraz, Sardar, Nimra, Peng, Kaoqing, Almutairi, Layla A., Duan, Xialo, Tanvir, Fouzia, Attia, Kotb A., Zeng, Gouhua, Gu, Di

Publikováno v: BMC Cancer; 7/22/2024, Vol. 24 Issue 1, p1-11, 11p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis.

Autor: Huang Y; Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Urology, Guangzhou, China; Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China; Guangzhou Institute of Urology, Guangzhou, China., He H; Nanshan School, Guangzhou Medical University, Guangzhou, China., Liang L; Nanshan School, Guangzhou Medical University, Guangzhou, China., Zhang Y; Nanshan School, Guangzhou Medical University, Guangzhou, China., Peng K; Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Urology, Guangzhou, China; Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China; Guangzhou Institute of Urology, Guangzhou, China., Wang Y; Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Urology, Guangzhou, China; Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China; Guangzhou Institute of Urology, Guangzhou, China., Wu J; Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Urology, Guangzhou, China; Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China; Guangzhou Institute of Urology, Guangzhou, China., Long X; Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Urology, Guangzhou, China; Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China; Guangzhou Institute of Urology, Guangzhou, China., Kairemo K; Departments of Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Goldberg H; Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA., Mendez LC; Department of Radiation Oncology, London Health Sciences Centre, London, ON, Canada., Gu D; Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Urology, Guangzhou, China; Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou, China; Guangzhou Institute of Urology, Guangzhou, China.

Publikováno v: Chinese clinical oncology [Chin Clin Oncol] 2024 Aug; Vol. 13 (4), pp. 64.